BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies

SAN DIEGO, April 14 BiPar Sciences, Inc. today announcedpositive preclinical data demonstrating the activity of its lead polyADP-ribose polymerase (PARP) inhibitor, BSI-201, in ovarian cancer models. Theresults highlight the anti-tumor activity of BSI-201 through PARP activityinhibition, tumor growth suppression, and extended survival inmulti-drug resistant xenograft models of ovarian cancer.

"We are excited to share emerging data on the therapeutic potential ofBSI-201 as a novel oncology platform drug, in the area of DNA repairinhibition," said Hoyoung Huh, M.D., Ph.D., President and CEO of BiParSciences. "BSI-201 represents an innovative therapeutic candidate which iswell positioned as both monotherapy and combination treatment in multiplesolid tumor settings including ovarian cancer."

The data presented at the 2008 American Association for Cancer Research(AACR) Annual Meeting today, evaluated BSI-201 as both a single agent and incombination with topotecan in human OVCAR-3 xenografts resistant toadriamycin, melphalan and cisplatin. Administered as monotherapy, BSI-201demonstrated significant tumor growth delay and improved survival. Incombination with topotecan, BSI-201 significantly inhibited tumor growth andincreased the percentage of complete tumor regressions, compared withtopotecan alone.

Based on the preclinical findings and positive Phase 1 results, BiPar iscurrently enrolling in a clinical trial of BSI-201 in combination withtopotecan in advanced ovarian cancer and will soon launch a Phase 2monotherapy trial in BRCA-negative ovarian cancer patients. These ovariancancer trials represent an important expansion of BiPar's on-going Phase 2programs in breast and brain cancer patients.

About BSI-201

BSI-201, a novel DNA repair inhibitor of PARP, is BiPar's lead productcandidate. BSI-201 is a small molecule candidate with the potential ofbecoming a superior, new class of treatment that possesses in-vivo activityacross a broad range of tumor types, both as monotherapy and in combinationwith standard-of-care chemotherapy regimens. In addition, Phase 1 studies ofBSI-201 have demonstrated that the drug is well-tolerated with minimal adverseside effects. BSI-201 is currently in Phase 2 clinical trials in multiplesolid tumor settings, including breast, ovarian, brain and uterine cancers.

About BiPar Sciences

BiPar Sciences is a drug development company with a therapeutic focus onnovel mechanisms of action in oncology. Our existing platform is based on DNArepair, specifically with poly ADP-ribose polymerase (PARP) inhibitors. BiParhas successfully advanced BSI-201 from an IND to a broad Phase 2 solid tumorclinical program in less than two years.

SOURCE BiPar Sciences, Inc.